Bayer Investor News | Bayer Global

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 442 News

1 - 10of 442 News

October 24, 2025

Not intended for U.S. and UK Media

Bayer’s Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause

September 22, 2025

Not intended for US and UK Media

Bayer first company to advance cell therapy as well as gene therapy against Parkinson’s disease

September 18, 2025

Not intended for U.S. and UK Media

New drug application for gadoquatrane accepted for review in China

August 30, 2025

Not intended for U.S. and UK Media

Data from Phase III VICTOR clinical trial of vericiguat presented at ESC Congress 2025

August 18, 2025

Monsanto reaches agreements in principle to resolve additional PCB cases at the Sky Valley Education Center

August 06, 2025

Bayer posts positive second quarter and progress on strategic priorities

July 31, 2025

Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States

July 30, 2025

Bayer submits registration applications for novel herbicide in four major markets

July 25, 2025

Not intended for U.S. and UK Media

Bayer provides regulatory update on elinzanetant in the U.S.

July 21, 2025

Not intended for U.S. and UK Media

Bayer’s Nubeqa™ (darolutamide) receives EU approval in third indication for patients with advanced prostate cancer

Inform Yourself on Special Topics

Control Weeds Not Farming

Control Weeds, Not Farming

Farmers discussing their weed management

Everything You Need to Know About Glyphosate

some-bayer-group-headquarters

Managing Glyphosate Litigation

woman harvesting carrots

Managing and Mitigating PCB Litigation Risk